HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypertension in the elderly: review of therapy with a hydroflumethiazide-reserpine combination.

Abstract
A retrospective analysis revealed that 125 geriatric patients had been treated for mild to moderate essential hypertension with a combination drug, each tablet of which contained 50 mg of hydroflumethiazide and 0.125 mg of reserpine. The dosage schedule was one tablet once daily for most patients. The duration of treatment ranged from 1 to 93 months (mean, 22.1 months). After one month of therapy, the decreases in mean systolic (-18.3 mm Hg) and mean diastolic (-6.6 mm Hg) blood pressure were statistically significant and these initial reductions were well maintained over a 6-year period, without signs of tachyphylaxis. Side effects were reported by 53 patients, but these usually were mild and typical of those associated with antihypertensive therapy; discontinuation of treatment was required in only 3 patients. Use of the hydroflumethiazide-reserpine combination was associated with several significant advantages, including convenient once-daily dosing, improved compliance, and decreased cost.
AuthorsE B Elkowitz
JournalJournal of the American Geriatrics Society (J Am Geriatr Soc) Vol. 27 Issue 11 Pg. 507-10 (Nov 1979) ISSN: 0002-8614 [Print] United States
PMID489858 (Publication Type: Journal Article)
Chemical References
  • Drug Combinations
  • Hydroflumethiazide
  • Reserpine
Topics
  • Aged
  • Blood Pressure
  • Drug Combinations
  • Female
  • Humans
  • Hydroflumethiazide (administration & dosage, therapeutic use)
  • Hypertension (drug therapy)
  • Male
  • Reserpine (administration & dosage, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: